{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:25:04Z","timestamp":1790036704202,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Affecting both livestock and humans, Rift Valley Fever is considered as one of the most important viral zoonoses in Africa. However, no licensed vaccines or effective treatments are yet available for human use. Naked DNA vaccines are an interesting approach since the virus is highly infectious and existing attenuated Rift Valley Fever virus vaccine strains display adverse effects in animal trials. In this study, gene-gun immunisations with cDNA encoding structural proteins of the Rift Valley Fever virus were evaluated in mice. The induced immune responses were analysed for the ability to protect mice against virus challenge.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Immunisation with cDNA encoding the nucleocapsid protein induced strong humoral and lymphocyte proliferative immune responses, and virus neutralising antibodies were acquired after vaccination with cDNA encoding the glycoproteins. Even though complete protection was not achieved by genetic immunisation, four out of eight, and five out of eight mice vaccinated with cDNA encoding the nucleocapsid protein or the glycoproteins, respectively, displayed no clinical signs of infection after challenge. In contrast, all fourteen control animals displayed clinical manifestations of Rift Valley Fever after challenge.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The appearance of Rift Valley Fever associated clinical signs were significantly decreased among the DNA vaccinated mice and further adjustment of this strategy may result in full protection against Rift Valley Fever.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1743-422x-6-6","type":"journal-article","created":{"date-parts":[[2009,1,17]],"date-time":"2009-01-17T07:12:48Z","timestamp":1232176368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs"],"prefix":"10.1186","volume":"6","author":[{"given":"Nina","family":"Lagerqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"N\u00e4slund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5ke","family":"Lundkvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Bouloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clas","family":"Ahlm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Bucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,1,17]]},"reference":[{"key":"520_CR1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.20506\/rst.23.2.1500","volume":"23","author":"G Gerdes","year":"2004","unstructured":"Gerdes G: Rift Valley fever. Rev Sci Tech 2004, 23: 613-623.","journal-title":"Rev Sci Tech"},{"key":"520_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0924-8579(02)00295-9","volume":"21","author":"H Balkhy","year":"2003","unstructured":"Balkhy H, Memish Z: Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. Int J Antimicrob Agents 2003, 21: 153-157. 10.1016\/S0924-8579(02)00295-9","journal-title":"Int J Antimicrob Agents"},{"key":"520_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-1364-7","volume-title":"The Bunyaviridae","author":"R Elliott","year":"1996","unstructured":"Elliott R: The Bunyaviridae. New York: Plenum Press; 1996."},{"key":"520_CR4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2174\/156652405774962263","volume":"5","author":"R Flick","year":"2005","unstructured":"Flick R, Bouloy M: Rift Valley fever virus. Curr Mol Med 2005, 5: 827-834. 10.2174\/156652405774962263","journal-title":"Curr Mol Med"},{"key":"520_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","volume":"18","author":"P Pittman","year":"1999","unstructured":"Pittman P, Liu C, Cannon T, Makuch R, Mangiafico J, Gibbs P, Peters C: Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 1999, 18: 181-189. 10.1016\/S0264-410X(99)00218-2","journal-title":"Vaccine"},{"key":"520_CR6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/oxfordjournals.aje.a113471","volume":"116","author":"J Kark","year":"1982","unstructured":"Kark J, Aynor Y, Peters C: A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. Am J Epidemiol 1982, 116: 808-820.","journal-title":"Am J Epidemiol"},{"key":"520_CR7","first-page":"1","volume-title":"Br J Exp Pathol","author":"KC Smithburn","year":"1949","unstructured":"Smithburn KC: Rift Valley Fever: The neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 1949, 1-16."},{"key":"520_CR8","first-page":"369","volume-title":"Foreign animal diseases","author":"S Metwally","year":"2008","unstructured":"Metwally S: Foreign animal diseases. 7th edition. Edited by: Brown C, Torres A. Boca Raton, FL: Boca Publications Group, Inc; 2008:369-376.","edition":"7"},{"key":"520_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/jmv.20624","volume":"78","author":"B Botros","year":"2006","unstructured":"Botros B, Omar A, Elian K, Mohamed G, Soliman A, Salib A, Salman D, Saad M, Earhart K: Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 2006, 78: 787-791. 10.1002\/jmv.20624","journal-title":"J Med Virol"},{"key":"520_CR10","first-page":"119","volume":"44","author":"J Coetzer","year":"1977","unstructured":"Coetzer J, Barnard B: Hydrops amnii in sheep associated with hydranencephaly and arthrogryposis with wesselsbron disease and rift valley fever viruses as aetiological agents. Onderstepoort J Vet Res 1977, 44: 119-126.","journal-title":"Onderstepoort J Vet Res"},{"key":"520_CR11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.20506\/rst.26.1.1737","volume":"26","author":"J Lubroth","year":"2007","unstructured":"Lubroth J, Rweyemamu M, Viljoen G, Diallo A, Dungu B, Amanfu W: Veterinary vaccines and their use in developing countries. Rev Sci Tech 2007, 26: 179-201.","journal-title":"Rev Sci Tech"},{"key":"520_CR12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","volume":"53","author":"R Muller","year":"1995","unstructured":"Muller R, Saluzzo J, Lopez N, Dreier T, Turell M, Smith J, Bouloy M: Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995, 53: 405-411.","journal-title":"Am J Trop Med Hyg"},{"key":"520_CR13","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","volume":"66","author":"H Caplen","year":"1985","unstructured":"Caplen H, Peters C, Bishop D: Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 1985, 66: 2271-2277. 10.1099\/0022-1317-66-10-2271","journal-title":"J Gen Virol"},{"key":"520_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0168-1702(97)00097-X","volume":"52","author":"P Vialat","year":"1997","unstructured":"Vialat P, Muller R, Vu T, Prehaud C, Bouloy M: Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res 1997, 52: 43-50. 10.1016\/S0168-1702(97)00097-X","journal-title":"Virus Res"},{"key":"520_CR15","first-page":"95","volume":"69","author":"P Hunter","year":"2002","unstructured":"Hunter P, Erasmus B, Vorster J: Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res 2002, 69: 95-98.","journal-title":"Onderstepoort J Vet Res"},{"key":"520_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00005-007-0044-4","volume":"55","author":"J Bel\u00e1kov\u00e1","year":"2007","unstructured":"Bel\u00e1kov\u00e1 J, Horynov\u00e1 M, Krupka M, Weigl E, Raska M: DNA vaccines: are they still just a powerful tool for the future? Arch Immunol Ther Exp (Warsz) 2007, 55: 387-398. 10.1007\/s00005-007-0044-4","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"520_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1023\/A:1008013720032","volume":"17","author":"M Giese","year":"1998","unstructured":"Giese M: DNA-antiviral vaccines: new developments and approaches-a review. Virus Genes 1998, 17: 219-232. 10.1023\/A:1008013720032","journal-title":"Virus Genes"},{"key":"520_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4049\/jimmunol.175.2.633","volume":"175","author":"J Donnelly","year":"2005","unstructured":"Donnelly J, Wahren B, Liu M: DNA vaccines: progress and challenges. J Immunol 2005, 175: 633-639.","journal-title":"J Immunol"},{"key":"520_CR19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1089\/hum.2006.17.1051","volume":"17","author":"M Liu","year":"2006","unstructured":"Liu M, Wahren B, Karlsson Hedestam G: DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006, 17: 1051-1061. 10.1089\/hum.2006.17.1051","journal-title":"Hum Gene Ther"},{"key":"520_CR20","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","volume":"24","author":"D Wallace","year":"2006","unstructured":"Wallace D, Ellis C, Espach A, Smith S, Greyling R, Viljoen G: Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 2006, 24: 7181-7189. 10.1016\/j.vaccine.2006.06.041","journal-title":"Vaccine"},{"key":"520_CR21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","volume":"170","author":"C Schmaljohn","year":"1989","unstructured":"Schmaljohn C, Parker M, Ennis W, Dalrymple J, Collett M, Suzich J, Schmaljohn A: Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 1989, 170: 184-192. 10.1016\/0042-6822(89)90365-6","journal-title":"Virology"},{"key":"520_CR22","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","volume":"24","author":"K Spik","year":"2006","unstructured":"Spik K, Shurtleff A, McElroy A, Guttieri M, Hooper J, SchmalJohn C: Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 2006, 24: 4657-4666. 10.1016\/j.vaccine.2005.08.034","journal-title":"Vaccine"},{"key":"520_CR23","first-page":"677","volume":"47","author":"Q Wang","year":"2007","unstructured":"Wang Q, Wang X, Hu S, Ge J, Bu Z: Study on DNA immune of envelope protein gene of Rift Valley Fever Virus. Wei Sheng Wu Xue Bao 2007, 47: 677-681. [abstract, article in Chinese]","journal-title":"Wei Sheng Wu Xue Bao"},{"key":"520_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/0035-9203(79)90004-X","volume":"73","author":"J Meegan","year":"1979","unstructured":"Meegan J: The Rift Valley fever epizootic in Egypt 1977\u201378. 1. Description of the epizzotic and virological studies. Trans R Soc Trop Med Hyg 1979, 73: 618-623. 10.1016\/0035-9203(79)90004-X","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"520_CR25","doi-asserted-by":"crossref","first-page":"8196","DOI":"10.1128\/JVI.73.10.8196-8200.1999","volume":"73","author":"A Sall","year":"1999","unstructured":"Sall A, Zanotto P, Sene O, Zeller H, Digoutte J, Thiongane Y, Bouloy M: Genetic reassortment of Rift Valley fever virus in nature. J Virol 1999, 73: 8196-8200.","journal-title":"J Virol"},{"key":"520_CR26","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1128\/JVI.02095-06","volume":"81","author":"B Bird","year":"2007","unstructured":"Bird B, Khristova M, Rollin P, Ksiazek T, Nichol S: Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry. J Virol 2007, 81: 2805-2816. 10.1128\/JVI.02095-06","journal-title":"J Virol"},{"key":"520_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.virusres.2004.05.005","volume":"105","author":"P Johansson","year":"2004","unstructured":"Johansson P, Olsson M, Lindgren L, Ahlm C, Elgh F, Holmstr\u00f6m A, Bucht G: Complete gene sequence of a human Puumala hantavirus isolate, Puumala Ume\u00e5\/hu: sequence comparison and characterisation of encoded gene products. Virus Res 2004, 105: 147-155. 10.1016\/j.virusres.2004.05.005","journal-title":"Virus Res"},{"key":"520_CR28","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.vaccine.2006.09.082","volume":"25","author":"M Lindkvist","year":"2007","unstructured":"Lindkvist M, Lahti K, Lillieh\u00f6\u00f6k B, Holmstr\u00f6m A, Ahlm C, Bucht G: Cross-reactive immune responses in mice after genetic vaccination with cDNA encoding hantavirus nucleocapsid proteins. Vaccine 2007, 25: 1690-1699. 10.1016\/j.vaccine.2006.09.082","journal-title":"Vaccine"},{"key":"520_CR29","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1016\/S0264-410X(02)00265-7","volume":"20","author":"P Johansson","year":"2002","unstructured":"Johansson P, Lindgren T, Lundstr\u00f6m M, Holmstr\u00f6m A, Elgh F, Bucht G: PCR-generated linear DNA fragments utilized as a hantavirus DNA vaccine. Vaccine 2002, 20: 3379-3388. 10.1016\/S0264-410X(02)00265-7","journal-title":"Vaccine"},{"key":"520_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0022-1759(90)90029-U","volume":"132","author":"Y Aida","year":"1990","unstructured":"Aida Y, Pabst M: Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 1990, 132: 191-195. 10.1016\/0022-1759(90)90029-U","journal-title":"J Immunol Methods"},{"key":"520_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jviromet.2008.04.007","volume":"151","author":"J N\u00e4slund","year":"2008","unstructured":"N\u00e4slund J, Lagerqvist N, Lundkvist A, Evander M, Ahlm C, Bucht G: Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR. J Virol Methods 2008, 151: 277-282. 10.1016\/j.jviromet.2008.04.007","journal-title":"J Virol Methods"},{"key":"520_CR32","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1016\/S0264-410X(01)00151-7","volume":"19","author":"G Bucht","year":"2001","unstructured":"Bucht G, Sj\u00f6lander K, Eriksson S, Lindgren L: Modifying the cellular transport of DNA-based vaccines alters the immune response to hantavirus nucleocapsid protein. Vaccine 2001, 19: 3820-3829. 10.1016\/S0264-410X(01)00151-7","journal-title":"Vaccine"},{"key":"520_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1023\/A:1007983306341","volume":"14","author":"P G\u00f6tt","year":"1997","unstructured":"G\u00f6tt P, Z\u00f6ller L, Darai G, Bautz E: A major antigenic domain of hantaviruses is located on the aminoproximal site of the viral nucleocapsid protein. Virus Genes 1997, 14: 31-40. 10.1023\/A:1007983306341","journal-title":"Virus Genes"},{"key":"520_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/088282402317340323","volume":"15","author":"A Lundkvist","year":"2002","unstructured":"Lundkvist A, Meisel H, Koletzki D, Lankinen H, Cifire F, Geldmacher A, Sibold C, G\u00f6tt P, Vaheri A, Kr\u00fcger D, Ulrich R: Mapping of B-cell epitopes in the nucleocapsid protein of Puumala hantavirus. Viral Immunol 2002, 15: 177-192. 10.1089\/088282402317340323","journal-title":"Viral Immunol"},{"key":"520_CR35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nrg2432","volume":"9","author":"M Kutzler","year":"2008","unstructured":"Kutzler M, Weiner D: DNA vaccines: ready for prime time? Nat Rev Genet 2008, 9: 776-788. 10.1038\/nrg2432","journal-title":"Nat Rev Genet"},{"key":"520_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.virol.2008.02.006","volume":"375","author":"G Gori Savellini","year":"2008","unstructured":"Gori Savellini G, Di Genova G, Terrosi C, Di Bonito P, Giorgi C, Valentini M, Docquier J, Cusi M: Immunization with Toscana virus N-Gc proteins protects mice against virus challenge. Virology 2008, 375: 521-528. 10.1016\/j.virol.2008.02.006","journal-title":"Virology"},{"key":"520_CR37","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.addr.2005.01.012","volume":"57","author":"H Dean","year":"2005","unstructured":"Dean H, Haynes J, Schmaljohn C: The role of particle-mediated DNA vaccines in biodefense preparedness. Adv Drug Deliv Rev 2005, 57: 1315-1342. 10.1016\/j.addr.2005.01.012","journal-title":"Adv Drug Deliv Rev"},{"key":"520_CR38","first-page":"371","volume-title":"Vaccines 89","author":"JMSEH Dalrymple","year":"1989","unstructured":"Dalrymple JMSEH, Kakach LT, Collet MS: Mapping protective determinants of Rift Valley Fever Virus using recombinant vaccinia viruses. Vaccines 89 1989, 371-375."},{"key":"520_CR39","first-page":"321","volume-title":"The biology of negative stranded viruses","author":"MS Collett","year":"1987","unstructured":"Collett MS, Keegan K, Hu SL, Sridhar P, Purchio AF, Ennis WH, Dalrymple JM: Protective subunit immunogens to RVFV from bacteria and recombinant vaccinia virus. In The biology of negative stranded viruses. Edited by: Mahy B, Kolakofsky D. New York, NY: Elsevier; 1987:321-329."},{"key":"520_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/BF01316748","volume":"121","author":"T Besselaar","year":"1991","unstructured":"Besselaar T, Blackburn N: Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies. Arch Virol 1991, 121: 111-124. 10.1007\/BF01316748","journal-title":"Arch Virol"},{"key":"520_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0923-2516(07)80002-1","volume":"145","author":"T Besselaar","year":"1994","unstructured":"Besselaar T, Blackburn N: The effect of neutralizing monoclonal antibodies on early events in Rift Valley fever virus infectivity. Res Virol 1994, 145: 13-19. 10.1016\/S0923-2516(07)80002-1","journal-title":"Res Virol"},{"key":"520_CR42","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1016\/j.vaccine.2008.07.042","volume":"26","author":"G Lorenzo","year":"2008","unstructured":"Lorenzo G, Mart\u00edn-Folgar R, Rodr\u00edguez F, Brun A: Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine 2008, 26: 5255-5262. 10.1016\/j.vaccine.2008.07.042","journal-title":"Vaccine"},{"key":"520_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1743-422X-5-82","volume":"5","author":"L Liu","year":"2008","unstructured":"Liu L, Celma C, Roy P: Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. Virol J 2008, 5: 82. 10.1186\/1743-422X-5-82","journal-title":"Virol J"},{"key":"520_CR44","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1086\/523650","volume":"196","author":"J Martin","year":"2007","unstructured":"Martin J, Pierson T, Hubka S, Rucker S, Gordon I, Enama M, Andrews C, Xu Q, Davis B, Nason M, Fay M, Koup Roederer M, Bailer R, Gomez P, Mascola J, Chang G-J, Nabel G, Graham B: A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007, 196: 1732-1740. 10.1086\/523650","journal-title":"J Infect Dis"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-6-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T09:51:09Z","timestamp":1630489869000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-6-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,17]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["520"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-6-6","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,17]]},"assertion":[{"value":"31 December 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"6"}}